SCHEMBL23258657

SCHEMBL23258657

CN1CCN(c2nc(CCCN)cn(-c3ccc(-n4ccnn4)cc3)c2=O)CC1

nearest known ligand 0.34

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.34
CYP19A1 P11511 1/20 0.34
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
KDM1A O60341 6/20 0.33
SYK P43405 1/20 0.32
USP1 O94782 2/20 0.31
CMA1 P23946 1/20 0.31
HTR2A P28223 1/20 0.31
DDX3X O00571 1/20 0.31
HTR3A P46098 1/20 0.31
HRH4 Q9H3N8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21552993 0.90 NOTUM (0.34) NOTUMCYP19A1CA12CA1CA2
SCHEMBL26035121 0.88 ALDH1A1 (0.35) NOTUMCYP19A1KDM1AHRH4
SCHEMBL21553092 0.86 NOTUM (0.34) NOTUMCYP19A1CA12CA1CA2
SCHEMBL29156939 0.85 KDM6B (0.39) NOTUMCYP19A1KDM1AUSP1CMA1
SCHEMBL21564837 0.83 HRH4 (0.40) HRH4
SCHEMBL21552967 0.82 DDX3X (0.38) NOTUMCYP19A1CMA1DDX3X
SCHEMBL23258205 0.81 SYK (0.39) SYKHRH4
SCHEMBL21552999 0.81 NOTUM (0.35) NOTUMCYP19A1KDM1ACMA1
SCHEMBL21553047 0.81 CMA1 (0.34) NOTUMCYP19A1KDM1ACMA1
SCHEMBL23258203 0.80 SYK (0.38) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A NOTUM 4680/4885CYP19A1 2956/4885CA12 4180/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A NOTUM 4635/4885CYP19A1 2345/4885CA12 4276/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A NOTUM 4680/4885CYP19A1 2956/4885CA12 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.